anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
INTRODUCTION: Continuous extracorporeal perfusion (ECP), or machine perfusion, holds promise for prolonged skeletal muscle preservation in limb ischemia-reperfusion injury. This study aimed to extend the amputation-to-replantation time window from currently 6 hours to 33 hours using a 24-hour ECP approach.
MATERIALS AND METHODS: Six large white pigs underwent surgical forelimb amputation under general anesthesia. After amputation, limbs were kept for 9 hours at room temperature and then perfused by 24-hour ECP with a modified histidine-tryptophan-ketoglutarate (HTK) solution. After ECP, limbs were orthotopically replanted and perfused in vivo for 12 hours. Clinical data, blood, and tissue samples were collected and analyzed.
RESULTS: All 6 forelimbs could be successfully replanted and in vivo reperfused for 12 hours after 9 hours of room temperature ischemia followed by 24 hours ECP. Adequate limb perfusion was observed after replantation as shown by thermography and laser Doppler imaging. All pigs survived without severe organ failure, and no significant increase in inflammatory cytokines was found. Macroscopy and histology showed marked interstitial muscular edema of the limbs, whereas myofiber necrosis was not evident, implying the preservation of muscular integrity.
CONCLUSIONS: The use of a 24-hour ECP has successfully extended limb preservation to 33 hours. The modified histidine-tryptophan-ketoglutarate perfusate demonstrated its ability for muscle protection. This innovative approach not only facilitates limb replantation after combat injuries, surmounting geographical barriers, but also broadens the prospects for well-matched limb allotransplants across countries and continents.
PURPOSE:To provide an antioxidant having strong oxidation inhibiting power and high-level safety and useful for prevention of oxidation of foods, cosmetics, etc., prepared by adding citric acid, malic acid, etc. to 3,4-dihydroxycinnamic ester. CONSTITUTION:The antioxidant is prepared by adding 5-200pts.wt. at least one compd. (synergist) selected from among citric acid, malic acid, ascorbic acid and ascorbic/stearic acid ester to 100pts.wt. compd. of the formula which is obtained by esterifying 3,4-dihydroxycinnamic acid with an alkanol.
PURPOSE: This review primarily aims to review the epidemiology, clinical characteristics, imaging, pathology, immunohistochemistry, diagnosis, differential diagnosis, treatment, and prognosis of Primary pulmonary myxoid sarcoma (PPMS) with EWS RNA binding protein 1::cAMP response element binding protein 1 (EWSR1::CREB1) fusion. It provides reference for the diagnosis and treatment of this disease.
METHODS: Retrospectively collected the literature about PPMS with EWSR1::CREB1 fusion, its clinical, radiology, histology, molecular characteristics and current treatment strategies were collated and analyzed. This review provides a detailed differential diagnosis of the disease.
RESULTS: PPMS is an exceptionally rare, low-grade malignant tumor of the lung. This tumor commonly infiltrates lung tissue and develops within bronchial passages. It is identified by a genetic rearrangement involving the EWSR1 gene and a distinct chromosomal translocation t(2; 22)(q33; q12). Variants include EWSR1::CREB1 fusion and EWS RNA binding protein 1::activating transcription factors (EWSR1::ATF1) fusion. PPMS with EWSR1::CREB1 fusion is more prevalent among middle-aged individuals and affects both sexes almost equally. Clinical symptoms are relatively non-specific, primarily including cough, hemoptysis, and weight loss. Most patients undergo surgery and experience a favorable prognosis. Further research is required to validate the effectiveness of alternative treatments for PPMS with EWSR1::CREB1 fusion.
CONCLUSION: EWSR1 rearrangement and EWSR1::CREB1 fusion are crucial genetic features of PPMS and serve as important diagnostic markers. Immunohistochemically, PPMS tests positive for EMA. In terms of treatment, surgery has been the primary approach in recent years. Therefore, the efficacy of other treatments still requires further investigation.
Oral transmucosal fentanyl citrate contains fentanyl, a Schedule II controlled substance. As an opioid, oral transmucosal fentanyl citrate exposes users to the risks of addiction, abuse, and misuse [see Drug Abuse and Dependence (9)].

Although the risk of addiction in any individual is unknown, it can occur in patients appropriately prescribed oral transmucosal fentanyl citrate. Addiction can occur at recommended dosages and if the drug is misused or abused.

Assess each patient’s risk for opioid addiction, abuse, or misuse prior to prescribing oral transmucosal fentanyl citrate, and monitor all patients receiving oral transmucosal fentanyl citrate for the development of these behaviors and conditions. Risks are increased in patients with a personal or family history of substance abuse (including drug or alcohol abuse or addiction) or mental illness (e.g., major depression). The potential for these risks should not, however, prevent the proper management of pain in any given patient. Patients at increased risk may be prescribed opioids such as oral transmucosal fentanyl citrate, but use in such patients necessitates intensive counseling about the risks and proper use of oral transmucosal fentanyl citrate along with intensive monitoring for signs of addiction, abuse, and misuse. Consider prescribing naloxone for the emergency treatment of opioid overdose [see Dosage and Administration (2.2), Warnings and Precautions (5.1)].

Opioids are sought by drug abusers and people with addiction disorders and are subject to criminal diversion. Consider these risks when prescribing or dispensing oral transmucosal fentanyl citrate. Strategies to reduce these risks include prescribing the drug in the smallest appropriate quantity and advising the patient on the proper disposal of unused drug [see Patient Counseling Information (17)]. Contact local state professional licensing board or state controlled substances authority for information on how to prevent and detect abuse or diversion of this product.
FIELD: biotechnology, molecular biology, biochemistry. SUBSTANCE: invention relates to nucleic acid structure for expression of active substance that is activated by enzyme protease releasing from mammalian cells and can be used in genetic therapy. Structure involves the following components: a) at least one promoter element; b) at least one DNA sequence that encodes active substance (protein B); c) at least one DNA sequence that encodes amino acid sequence (structural part C) that can be cleaved specifically by enzyme that is released from mammalian cells; d) at least one DNA sequence that encodes peptide or protein (structural part D) that binds with corresponding active compound (protein B) through cleavable amino acid sequence (structural part C) and inhibits activity of this active compound (protein B). The advantage of invention involves the development of structure that can release active substance with using proteases producing by cells. EFFECT: valuable biological properties of structure. 16 cl, 3 dwg, 2 tbl
BACKGROUND AND AIMS: The economic impact of managing patients with hepatitis C virus (HCV) infection remains unknown. This study aimed to assess the economic burden of chronic HCV infection from a national health insurance perspective and the impact of direct-acting antivirals (DAAs) using nationwide real-world data.
METHODS: Patients with chronic HCV infection were identified from the French Health Insurance Claims Databases (SNDS) and matched for age and sex to the general population. Health resource utilization and reimbursements were summarized according to healthcare expenditure items from 2012 to 2021. The economic burden attributable to chronic HCV infection was evaluated over a 10-year period. Finally, the impact of DAAs was estimated using economic data derived from the SNDS.
RESULTS: A total of 145 187 patients with chronic HCV infection were identified. Among the patients eligible for DAA therapy, 81.5% had received DAA by the end of 2021. Over a 10-year period, managing patients with chronic HCV infection resulted in an additional cost of €9.71 billion (95% confidence interval [CI]: €9.66-€9.78 billion) or €9191 (95% CI: €9134-€9252) per patient per year compared to the general population. After DAA therapy, patients with chronic HCV infection had a higher economic burden than the general population, with an additional cost of €5781 (95% CI: €5540-€6028) per patient at the fifth-year post-DAA therapy.
CONCLUSIONS: A significant economic burden persists among patients with HCV infection after DAA treatment. The high proportion of patients not treated with DAA therapy supports reinforcing policies for universal access.
Cosmetic facial serum. To be used twice daily on lesional areas of the face for 12 weeks.
PURPOSE: Single-sided deafness (SSD) presents significant challenges for patients, including compromised sound localization, reduced speech recognition, and often, tinnitus. These issues are typically addressed using interventions such as cochlear implantation (CI) and bone conduction implant (BCI). However, evidence regarding the efficacy of BCI in reducing tinnitus in SSD patients remains limited. This study explored the ability of a novel active transcutaneous BCI (Bonebridge BCI602) to alleviate tinnitus in SSD patients.
STUDY DESIGN: Prospective cohort multicenter study.
SETTING: Tertiary referral hospitals.
METHODS: A prospective multicenter study of 30 SSD patients was conducted. The patients were divided into two groups: those with (n = 19) and without (n = 11) tinnitus. Audiometric assessments, subjective questionnaires including the Abbreviated Profile of Hearing Aid Benefit (APHAB) and the Bern Benefit in Single-Sided Deafness (BBSS), and tinnitus evaluations with the Tinnitus Handicap Inventory (THI) and tinnitogram were conducted before and after BCI surgery.
RESULTS: THI scores after surgery were significantly reduced in SSD patients with tinnitus. Subjective satisfaction improved in both the tinnitus and non-tinnitus groups; however, the former group exhibited a significantly greater improvement in the APHAB questionnaire score. According to tinnitograms, the loudness of tinnitus decreased, particularly in patients with ipsilateral tinnitus. Patients with residual hearing had greater reductions in their THI scores. However, three patients without residual hearing had a relative worsening of tinnitus after surgery.
CONCLUSION: The Bonebridge BCI602 effectively reduced tinnitus in SSD patients, particularly in those with residual hearing. Subjective satisfaction improved in both the tinnitus and non-tinnitus groups. These findings demonstrate the therapeutic potential of BCI for managing SSD and associated tinnitus.
Disclosed herein are isolated immunogens including variant hepatitis B surface antigens (HBsAgs). In an example, a variant HBsAg includes a HBsAg with one or more transmembrane domains of the HBsAg replaced with a gp41 antigenic insert. The antigenic insert can include an antigenic polypeptide fragment of gp41 including the membrane proximal region of gp41 and a transmembrane membrane region of gp41. The replacement of a membrane spanning domain of HBsAg with a membrane spanning domain of gp41 anchors gp41 into HBsAg in virtually the identical orientation as on HIV virions and correctly orients the nearby MPR on the lipid layer. Thus, the disclosed variant HBsAgs display the neutralization-sensitive MPR in association with a lipid layer, while presenting it at the most immunogenic site on HBsAg. Also disclosed are uses of these variant HBsAgs, and nucleic acids encoding variant HBsAgs, such as to induce an immune response to HIV-1.
Seretide® Accuhaler® (fluticasone 500 μg plus salmeterol 50 μg/actuation), 1 inhalation b.i.d. (daily dose of fluticasone 1000 μg plus salmeterol 100 μg).
To provide a body temperature measuring device that allows a user to measure his or her body temperature in a non-contact manner while suppressing an error of a measured value.SOLUTION: A body temperature measuring device 1 includes a pair of light sources 20, a temperature sensor 30, and a mirror 40. The pair of light sources 20 emits a colored light to a user 9. The temperature sensor 30 measures a body temperature of the user 9 in a non-contact manner. The mirror 40 reflects the user 9. The user 9 adjusts his or her position while looking at the mirror 40 so that the spots Bs of a pair of colored lights emitted from the pair of light sources 20 superpose at one point. Thereby, a distance from the temperature sensor 30 to the user 9 can be adjusted to a fixed distance. The user 9 can consequently measure his or her temperature in a non-contact manner, and suppress an error of a measured value output from the temperature sensor 30.SELECTED DRAWING: Figure 5
Subjects complete baseline assessment, 3 wks of training with versions of the tasks using neutral stimuli, and a post-training assessment. Subjects will be contacted monthly for 3 months after discharge for follow-up interviews.
Background - In the context of hypogonadism, androgen supplementation is clearly beneficial, particularly in younger males. The benefits of therapy in men with milder degrees of hypogonadism, and elderly males with testosterone deficiency, are less clear-cut. Several options are available for androgen replacement in adult men. Oral testosterone, intramuscular injections, subcutaneous implants and transdermal therapy have all been used. Each mode of delivery has advantages and drawbacks. Several alkylated derivatives of T are available for oral or sublingual use, including methyl testosterone and fluoxymesterone. However, they are not recommended for use as replacement therapy because of their associated adverse effects.

Study Design - This is a multi-center, double-blind, placebo-controlled, parallel group, randomized study of DHT-Gel versus placebo gel in male subjects ages 55-80 years inclusive with low serum testosterone and symptoms compatible with the clinical diagnosis of hypogonadism. Total enrollment for this study will be approximately 120 subjects (40 subjects for each treatment group). Subjects will be treated with 35 mg/day DHT, 70 mg/day DHT, or placebo gel for 6 months. All subjects will apply the gel once daily. Up to 9 months of study participation, including up to 2 months of screening and a 1-month follow-up period, will be required by the protocol.

The primary efficacy endpoint in this study is change in body composition as determined by DEXA scan. Secondary endpoints in this study include change in sexual libido, and overall function and mood, and normalization of serum androgen levels. A subset of sites will perform strength assessments, which will include handgrip dynamometry, and upper and lower body strength tests.
Participants were asked to walk with their major caregivers for 20 minutes every day during the study period. After the study, they were taught how to ride a bicycle to recognize their contribution as controls.
Although the majority of hospitalized VA smokers receive some form of cessation counseling during hospitalization, few receive outpatient cessation counseling and/or pharmacotherapy following discharge, which are key factors associated with long-term cessation. The primary objective of this research study is to determine whether a nurse-initiated intervention, which couples brief inpatient counseling and proactive telephone counseling by a centralized tobacco quitline, improves 6-month cessation rates in hospitalized VA smokers. Co-primary aims are to determine whether the intervention improves the prescription of recommended pharmacotherapy for smoking cessation and the referral of patients for telephone counseling (or other outpatient cessation counseling). We will perform a quasi-experimental before-after trial in hospitalized patients, aged 18 or older, who smoke at least one cigarette per day on average. After a 6-month baseline period, we will implement the intervention and enroll a separate cohort of patients over the subsequent 6 months. The intervention will include: 1) nurse training in delivery of bedside cessation counseling, 2) use of CPRS-based practice tools (to streamline nursing assessment and documentation, to facilitate prescription of pharmacotherapy), 3) computerized referral of motivated inpatients for proactive telephone counseling, and 4) use of nursing peer leaders to provide coaching and performance feedback to ward nurses. Enrolled patients will be contacted by telephone at 3 and 6 months to assess 7-day point prevalence abstinence and prolonged abstinence (with biochemical confirmation of self-reported quitters at 6 months). We will identify barriers and facilitators to implementation by using clinician focus groups, and will assess attitudes of staff nurses toward cessation counseling by questionnaire. We will also conduct semi-structured interviews in a subsample of patients and nurses to assess perceptions of the intervention, and will use content analysis to interpret the data.
The invention discloses a sulfuric acid cefquinome frozen powder injection, belonging to the field of veterinary drug preparation. The frozen powder injection comprises the ingredients of, by weight, 2.22-6.67 parts of sulfuric acid cefquinome, 5-20 parts of enveloping auxiliary material, 2-10 parts of freeze-dried excipient and the balance of injection water; wherein the weight ratio of the sulfuric acid cefquinome and the injection water is 1:5-20. The invention further discloses a preparation method of the sulfuric acid cefquinome frozen powder injection. Firstly, the sulfuric acid cefquinome frozen powder injection disclosed by the invention has good stability and high activity, and the appearance and the activity barely change after the sulfuric acid cefquinome frozen powder injection is laid aside for six months. Secondly, the sulfuric acid cefquinome frozen powder injection has high curative effect, accordingly, the injection times and the stress reactions of an animal can be reduced and the animal welfare can be improved. Moreover, the invention is more applicable for industrialization production.
Disclosed is Chinese herbal medicine composition for treating puerperal diseases and a preparation method of the Chinese herbal medicine composition. The Chinese herbal medicine composition comprises, by weight, 20-60 parts of elecampane, 20-70 parts of folium isatidis, 10-40 parts of ginseng, 10-50 parts of scutellaria baicalensis, 20-70 parts of jujube, 20-60 parts of hawthorn, 10-40 parts of eucommia ulmoides, 20-60 parts of radix liriopes, 20-60 parts of loquat leaves, 15-60 parts of sweet wormwood, 10-60 parts of pine pollen, 10-60 parts of kelp, 10-60 parts of radix curcumae, 10-60 parts of rhizoma anemarrhenae, 15-65 parts of quispualis indica, and 10-40 parts of liquorice. The Chinese herbal medicine composition is made through soaking, boiling and alcohol extraction. The Chinese herbal medicine composition can treat 360 cases of puerperal disease, and general efficacy is up to 94.4%. The Chinese herbal medicine composition has remarkable effect and has no untoward effect and toxic and side effect. Therefore, the Chinese has remarkable curative effect on treatment of puerperal diseases and high popularization value.
PURPOSE:A CSF sustained release pharmaceutical, obtained by containing a colony stimulating factor (CSF) in a specific carrier, e.g. collagen, gelatin, etc., useful for recovering granulocytopenia in leukocytes, cancer, etc., and capable of sustaining release for a long period. CONSTITUTION:A CSF sustained release pharmaceutical obtained by blending, e.g. an aqueous solution of a colony stimulating factor (CSF) with an aqueous solution of a carrier, capable of in vivo administration and consisting of a low toxic compound, preferably collagen, gelatin or a mixture thereof, concentrating and drying the resultant blend. Thus, the CSF is entrapped in the carrier. The resultant material is then suitably processed depending on the purpose. For example, the material is pulverized to an injectable particle diameter while cooling with dry ice, etc., and suspended in a solvent for injection to afford a sustained release suspension type injection. Alternatively, the material is molded into a spherical, cylindrical shape, etc., and can be administered by a method of in vivo imbedding, intracoelomic inserting, etc. Multipotential SCF, granulocytic SCF, etc., are cited as the CSF.
Patients previously treated with selected immunotherapies and platinum-based chemotherapy. Nivolumab over 30 min IV infusion (240 mg IV every 2 weeks or 480 mg every 4 weeks) and sitravatinib 120 mg orally once per day continuously in 28-day cycles.
The use of complementary and alternative medicine (CAM) in the United States has seen a steady and steep rise over the past two decades. A national survey of over 31,000 adults found that 36% of respondents had used CAM therapies in the last month, and this estimate increased to 62% when prayer for health reasons was included. Second, this same survey showed that CAM is often used to treat symptoms and illnesses associated with stress such as depression, anxiety, back and neck pain, and gastrointestinal disorders. Finally, many individuals experiencing high levels of stress lack access to conventional medicine due to lack of medical insurance, possibly increasing the attractiveness of CAM for these individuals. This ongoing systematic characterization of CAM usage patterns in civilian populations has not been mirrored in active military and military Veteran populations across the United States. Data from the less than handful of studies that have been conducted thus far, suggest that CAM usage patterns in military and military Veteran populations are influenced by demographics and certain medical conditions, as well as dissatisfaction with certain aspects of conventional care. While there appears to be some similarity between civilian and non-civilians populations, there remains much to be known in the latter population.
The efficacy of teriparatide for treating glucocorticoid-induced osteoporosis was assessed in a randomized, double-blind, active-controlled trial of 428 patients (19% men, 81% women) aged 22 to 89 years (mean 57 years) treated with ≥5 mg/day prednisone or equivalent for a minimum of 3 months. The duration of the trial was 18 months. In the trial 214 patients were treated with teriparatide 20 mcg given subcutaneously once daily. In the teriparatide group, the baseline median glucocorticoid dose was 7.5 mg/day and the baseline median duration of glucocorticoid use was 1.5 years. The mean (SD) baseline lumbar spine BMD was 0.85 ± 0.13 g/cm2 and lumbar spine BMD T-score was –2.5 ± 1 (number of standard deviations below the mean BMD value for healthy adults). A total of 30% of patients had prevalent vertebral fracture(s) and 43% had prior non-vertebral fracture(s). The patients had chronic rheumatologic, respiratory or other diseases that required sustained glucocorticoid therapy. All patients received 1000 mg of calcium plus 800 IU of vitamin D supplementation per day. 

Because of differences in mechanism of action (anabolic vs. anti-resorptive) and lack of clarity regarding differences in BMD as an adequate predictor of fracture efficacy, data on the active comparator are not presented.

Effect on Bone Mineral Density (BMD)

In patients with glucocorticoid-induced osteoporosis, teriparatide increased lumbar spine BMD compared with baseline at 3 months through 18 months of treatment. In patients treated with teriparatide, the mean percent change in BMD from baseline to endpoint was 7.2% at the lumbar spine, 3.6% at the total hip, and 3.7% at the femoral neck (p<0.001 all sites). The relative treatment effects of teriparatide were consistent in subgroups defined by gender, age, geographic region, body mass index, underlying disease, prevalent vertebral fracture, baseline glucocorticoid dose, prior bisphosphonate use, and glucocorticoid discontinuation during trial.